Please ensure Javascript is enabled for purposes of website accessibility
top of page

Community Job Openings

Welcome to our community job board where we curate relevant job openings to share with our community. If you have a job post to share, we invite you to reach out to

Updated March 13, 2024

  1. Project Manager, Innovative Genomics Institute: The Innovative Genomics Institute is a joint effort between the Bay Area’s leading scientific research institutions, UC Berkeley and UC San Francisco, with affiliates at UC Davis, Lawrence Berkeley National Laboratory, Lawrence Livermore National Laboratory, Gladstone Institutes, and other institutions. The IGI’s diverse group of leading scientists have powerful interdisciplinary expertise. They conduct world-class research, driven by the real possibility of using genome engineering to treat human diseases, end hunger, and respond to climate change. In addition to our scientific efforts, the IGI is committed to advancing public understanding of genome engineering, providing resources for the broader community, and guiding the ethical use of these technologies. Please click here to learn more.

Updated December 1, 2023

  1. Research technician DCRT: Would you like to develop genetic therapies for patients with rare neurological disorders? Are you interested in using new cellular modelling systems to study human disease? If you are interested in joining a very young, international team at the Dutch Center for RNA Therapeutics, visit LUMC for more information.

  2. Synofzik Lab: Translational Genomics of Neurodegenerative Diseases (ataxias, frontotemporal dementia, early-onset Alzheimer's dementia, amyotrophic lateral sclerosis, rare genetic neurodegenerative diseases). Research priorities of our group are: translational pipeline from gene to targeted mechanistic therapy, with the following core clusters: next-generation sequencing genomics (WES, WGS, RNAseq). Fluid biomarkers in CSF and blood. Sensor-based digital motor outcomes. Clinical outcome parameters and natural history studies. Innovative first-in-human therapy studies, e.g. with customized n-of-1 antisense oligonucleotides (ASOs).

  3. N1C Patient Identification Group (volunteer position): The N1C Patient Identification group is establishing guidelines and training material to assess genetic variants for ASO amenability and is looking for volunteer assessors to test the training. We would like to invite interested volunteers who have a background in genetics and are familiar with variant nomenclature but have not yet been trained to assess variants for ASO amenability to participate. Assessors will receive training material and example variants to evaluate. They will then be asked for feedback on the training material and receive themselves feedback on their evaluations. The aim is to publish the training materials and the outcomes of the evaluations from trained and untrained assessors to identify if the N1C training material suffices in guiding assessors to make the correct decisions. If you would like to participate, please reach out to David Cheerie ( or Marlen Lauffer ( by the 15th December 2023. Trainings will run from January to March 2024 and we expect the workload to be around 2-3 working days.



bottom of page